scholarly journals OTUD7A Regulates Inflammation- and Immune-Related Gene Expression in Goose Fatty Liver

Agriculture ◽  
2022 ◽  
Vol 12 (1) ◽  
pp. 105
Author(s):  
Minmeng Zhao ◽  
Kang Wen ◽  
Xiang Fan ◽  
Qingyun Sun ◽  
Diego Jauregui ◽  
...  

OTU deubiquitinase 7A (OTUD7A) can suppress inflammation signaling pathways, but it is unclear whether the gene can inhibit inflammation in goose fatty liver. In order to investigate the functions of OTUD7A and identify the genes and pathways subjected to the regulation of OTUD7A in the formation of goose fatty liver, we conducted transcriptomic analysis of cells, which revealed several genes related to inflammation and immunity that were significantly differentially expressed after OTUD7A overexpression. Moreover, the expression of interferon-induced protein with tetratricopeptide repeats 5 (IFIT5), tumor necrosis factor ligand superfamily member 8 (TNFSF8), sterile alpha motif domain-containing protein 9 (SAMD9), radical S-adenosyl methionine domain-containing protein 2 (RSAD2), interferon-induced GTP-binding protein Mx1 (MX1), and interferon-induced guanylate binding protein 1-like (GBP1) was inhibited by OTUD7A overexpression but induced by OTUD7A knockdown with small interfering RNA in goose hepatocytes. Furthermore, the mRNA expression of IFIT5, TNFSF8, SAMD9, RSAD2, MX1, and GBP1 was downregulated, whereas OTUD7A expression was upregulated in goose fatty liver after 12 days of overfeeding. In contrast, the expression patterns of these genes showed nearly the opposite trend after 24 days of overfeeding. Taken together, these findings indicate that OTUD7A regulates the expression of inflammation- and immune-related genes in the development of goose fatty liver.

Hepatology ◽  
2013 ◽  
Vol 57 (2) ◽  
pp. 566-576 ◽  
Author(s):  
Marcela Aparicio-Vergara ◽  
Pascal P.H. Hommelberg ◽  
Marijke Schreurs ◽  
Nanda Gruben ◽  
Rinke Stienstra ◽  
...  

2018 ◽  
Vol 120 (5) ◽  
pp. 8784-8791
Author(s):  
Marzieh Taheri ◽  
Pegah Ghandil ◽  
Seyyed Jalal Hashemi ◽  
Mehri Ghafourian ◽  
Abdol Rahim Masjedi Zadeh ◽  
...  

2003 ◽  
Vol 111 (03) ◽  
pp. 154-161 ◽  
Author(s):  
B. Wetzka ◽  
B. Sehringer ◽  
W. Schäfer ◽  
S. Biller ◽  
C. Hör ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Feng Gao ◽  
Kenneth I. Zheng ◽  
Hua-Dong Yan ◽  
Qing-Feng Sun ◽  
Ke-Hua Pan ◽  
...  

Background and AimCirculating levels of interleukin (IL)-6, a well-known inflammatory cytokine, are often elevated in coronavirus disease-2019 (COVID-19). Elevated IL-6 levels are also observed in patients with metabolic dysfunction-associated fatty liver disease (MAFLD). Our study aimed to describe the association between circulating IL-6 levels and MAFLD at hospital admission with risk of severe COVID-19.MethodsA total of 167 patients with laboratory-confirmed COVID-19 from three Chinese hospitals were enrolled. Circulating levels of IL-2, IL-4, IL-6, IL-10, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ were measured at admission. All patients were screened for fatty liver by computed tomography. Forty-six patients were diagnosed as MAFLD.ResultsPatients with MAFLD (n = 46) had higher serum IL-6 levels (median 7.1 [interquartile range, 4.3–20.0] vs. 4.8 [2.6–11.6] pg/mL, p = 0.030) compared to their counterparts without MAFLD (n = 121). After adjustment for age and sex, patients with MAFLD had a ~2.6-fold higher risk of having severe COVID-19 than those without MAFLD. After adjustment for age, sex and metabolic co-morbidities, increased serum IL-6 levels remained associated with higher risk of severe COVID-19, especially among infected patients with MAFLD (adjusted-odds ratio 1.14, 95% CI 1.05–1.23; p = 0.002). There was a significant interaction effect between serum IL-6 levels and MAFLD for risk of severe COVID-19 (p for interaction = 0.008).ConclusionsPatients with MAFLD and elevated serum IL-6 levels at admission are at higher risk for severe illness from COVID-19.


Sign in / Sign up

Export Citation Format

Share Document